Host response to respiratory syncytial virus infection

Current Opinion in Infectious Diseases

Volumn 28, Issue 3, 2015, Pages 259-266

  Arruvito, Lourdes ^a   Raiden, Silvina ^b   Geffner, Jorge ^c  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^c Universidad de Buenos Aires   (Argentina)

Author keywords

bronchiolitis; immunity; neonatal; pathogenesis; respiratory syncytial virus

Indexed keywords

CD8 ANTIGEN; PATTERN RECOGNITION RECEPTOR; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; CHILD HOSPITALIZATION; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFANT MORTALITY; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; TH1 CELL; TH17 CELL; TH2 CELL; VIRAL BRONCHIOLITIS; ANIMAL; DISEASE MODEL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MOUSE; PATHOPHYSIOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFANT; MICE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES, REGULATORY;

EID: 84929460224     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000159     Document Type: Review

References (145)

1. Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 2013; 372:39-57.
2. Meng J, Stobart CC, Hotard AL, et al. An overview of respiratory syncytial virus. PLoS Pathog 2014; 10:e1004016.
3. Rodriguez R, Ramilo O. Respiratory syncytial virus: how, why and what to do. J Infect 2014; 68 (Suppl 1):S115-S118.
4. Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus-a comprehensive review. Clin Rev Allergy Immunol 2013; 45:331-379.
5. Simoes EA, Carbonell-Estrany X, Rieger CH, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010; 126:256-262.
6. Piedimonte G, Perez MK. Alternative mechanisms for respiratory syncytial virus (RSV) infection and persistence: could RSV be transmitted through the placenta and persist into developing fetal lungs? Curr Opin Pharmacol 2014; 16:82-88.
7. Habibi MS, Openshaw PJ. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis 2012; 25:687-694.
8. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588-598.
9. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-1555.
10. Winterstein AG, Knox CA, Kubilis P, et al. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr 2013; 167:1118-1124.
11. Hasegawa K, Pate BM, Mansbach JM, et al. Risk factors for requiring intensive care among children admitted to ward with bronchiolitis. Acad Pediatr 2015; 15:77-81.
12. Dotan M, Ashkenazi-Hoffnung L, Samra Z, et al. Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins. Isr Med Assoc J 2013; 15:701-704.
13. Carroll KN, Griffin MR, Edwards KM, et al. Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties. Pediatr Infect Dis J 2012; 31:e229-e231.
14. Zhang XB, Liu LJ, Qian LL, et al. Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants. World J Pediatr 2014; 10:360-364.
15. Lanari M, Vandini S, Capretti MG, et al. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res 2014; 2014:850831.
16. Yi H, Lanctot KL, Bont L, et al. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics 2014; 133:1031-1037.
17. Ferolla FM, Hijano DR, Acosta PL, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med 2013; 187:983-990.
18. Wijngaard CC, Asten L, Koopmans MP, et al. Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children. PLoS One 2012; 7:e31197.
19. van Asten L, van den Wijngaard C, van Pelt W, et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis 2012; 206:628-639.
20. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57:1069-1077.
21. Moore ML, Stokes KL, Hartert TV. The impact of viral genotype on pathogenesis and disease severity: respiratory syncytial virus and human rhinoviruses. Curr Opin Immunol 2013; 25:761-768.
22. Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 2013; 372:3-38.
23. Anderson LJ. Respiratory syncytial virus vaccine development. Semin Immunol 2013; 25:160-171.
24. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013; 372:83-104.
25. Jorquera PA, Oakley KE, Tripp RA. Advances in and the potential of vaccines for respiratory syncytial virus. Expert Rev Respir Med 2013; 7:411-427.
26. Lambert L, Sagfors AM, Openshaw PJ, et al. Immunity to RSV in early-life. Front Immunol 2014; 5:466.
27. Gomez RS, Guisle-Marsollier I, Bohmwald K, et al. Respiratory syncytial virus: pathology, therapeutic drugs and prophylaxis. Immunol Lett 2014; 162:237-247.
28. Alexander-Miller MA. Vaccines against respiratory viral pathogens for use in neonates: opportunities and challenges. J Immunol 2014; 193:5363-5369.
29. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol 2012; 12:636-648.
30. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in early life. Front Immunol 2014; 5:391.
31. Huygens A, Dauby N, Vermijlen D, et al. Immunity to cytomegalovirus in early life. Front Immunol 2014; 5:552.
32. Piccini P, Chiappini E, Tortoli E, et al. Clinical peculiarities of tuberculosis. BMC Infect Dis 2014; 14 (Suppl 1):S4.
33. Vanden Driessche K, Persson A, Marais BJ, et al. Immune vulnerability of infants to tuberculosis. Clin Dev Immunol 2013; 2013:781320.
34. Bates I, Fenton C, Gruber J, et al. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis 2004; 4:267-277.
35. Christensen KL, Holman RC, Steiner CA, et al. Infectious disease hospitalizations in the United States. Clin Infect Dis 2009; 49:1025-1035.
36. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014; 14:24-35.
37. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7:379-390.
38. Ghazal P, Dickinson P, Smith CL. Early life response to infection. Curr Opin Infect Dis 2013; 26:213-218.
39. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol 2014; 35:299-310.
40. Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol 2013; 13:551-565.
41. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 2014; 32:461-488.
42. Barbalat R, Ewald SE, Mouchess ML, et al. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011; 29:185-214.
43. Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLRmediated responses are distinct from those of adults. J Immunol 2009; 183:7150-7160.
44. Slavica L, Nordstrom I, Karlsson MN, et al. TLR3 impairment in human newborns. J Leukoc Biol 2013; 94:1003-1011.
45. Gbedande K, Varani S, Ibitokou S, et al. Malaria modifies neonatal and earlylife toll-like receptor cytokine responses. Infect Immun 2013; 81:2686-2696.
46. Cuenca AG, Wynn JL, Moldawer LL, et al. Role of innate immunity in neonatal infection. Am J Perinatol 2013; 30:105-112.
47. Danis B, George TC, Goriely S, et al. Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur J Immunol 2008; 38:507-517.
48. Nguyen M, Leuridan E, Zhang T, et al. Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS One 2010; 5:e10407.
49. Belnoue E, Fontannaz P, Rochat AF, et al. Functional limitations of plasmacytoid dendritic cells limit type I interferon, T cell responses and virus control in early life. PLoS One 2013; 8:e85302.
50. Lin SJ, Yang MH, Chao HC, et al. Effect of interleukin-15 and Flt3-ligand on natural killer cell expansion and activation: umbilical cord vs. adult peripheral blood mononuclear cells. Pediatr Allergy Immunol 2000; 11:168-174.
51. Lee YC, Lin SJ. Natural killer cell in the developing life. J Perinat Med jpm 2015; 44:11-17.
52. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 2009; 30:585-591.
53. Debock I, Flamand V. Unbalanced neonatal CD4(\+) T-cell immunity. Front Immunol 2014; 5:393.
54. Mastelic B, Kamath AT, Fontannaz P, et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J Immunol 2012; 189:5764-5772.
55. Debock I, Jaworski K, Chadlaoui H, et al. Neonatal follicular Th cell responses are impaired and modulated by IL-4. J Immunol 2013; 191:1231-1239.
56. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185-194.
57. Rudd BD, Venturi V, Smith NL, et al. Acute neonatal infections 'lock-in' a suboptimal CD8\+ T cell repertoire with impaired recall responses. PLoS Pathog 2013; 9:e1003572.
58. Smith NL, Wissink E, Wang J, et al. Rapid proliferation and differentiation impairs the development of memory CD8\+ T cells in early life. J Immunol 2014; 193:177-184.
59. Ruckwardt TJ, Malloy AM, Morabito KM, et al. Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8\+ T cell response. PLoS Pathog 2014; 10:e1003934.
60. Kolli D, Velayutham TS, Casola A. Host-viral interactions: role of pattern recognition receptors (PRRs) in human pneumovirus infections. Pathogens 2013; 2:232-263.
61. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev 2013; 255:25-39.
62. Rallabhandi P, Phillips RL, Boukhvalova MS, et al. Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2. MBio 2012; 3:e00218-12.
63. Gay NJ, Symmons MF, GangloffM, et al. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014; 14:546-558.
64. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
65. Murawski MR, Bowen GN, Cerny AM, et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009; 83:1492-1500.
66. Rudd BD, Smit JJ, Flavell RA, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 2006; 176:1937-1942.
67. Lukacs NW, Smit JJ, Mukherjee S, et al. Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. J Immunol 2010; 185:2231-2239.
68. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011; 29:447-491.
69. Bhoj VG, Sun Q, Bhoj EJ, et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci USA 2008; 105:14046-14051.
70. Foronjy RF, Dabo AJ, Cummins N, et al. Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol 2014; 15:41.
71. Foronjy RF, Taggart CC, Dabo AJ, et al. Type-I interferons induce lung protease responses following respiratory syncytial virus infection via RIG-Ilike receptors. Mucosal Immunol 2015; 8:161-175.
72. Grandvaux N, Guan X, Yoboua F, et al. Sustained activation of interferon regulatory factor 3 during infection by paramyxoviruses requires MDA5. J Innate Immun 2014; 6:650-662.
73. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-568.
74. Goritzka M, Durant LR, Pereira C, et al. Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol 2014; 88:6128-6136.
75. Barik S. Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr Top Microbiol Immunol 2013; 372:173-191.
76. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med 2013; 10:e1001549.
77. Openshaw PJ. A gene expression signature for RSV: clinical implications and limitations. PLoS Med 2013; 10:e1001550.
78. McNamara PS, Ritson P, Selby A, et al. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 2003; 88:922-926.
79. Johnson JE, Gonzales RA, Olson SJ, et al. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007; 20:108-119.
80. Stokes KL, Currier MG, Sakamoto K, et al. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J Virol 2013; 87:10070-10082.
81. Noah TL, Ivins SS, Murphy P, et al. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin Immunol 2002; 104:86-95.
82. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000; 55:1023-1027.
83. Gill MA, Palucka AK, Barton T, et al. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis 2005; 191:1105-1115.
84. Wang H, Peters N, Schwarze J. Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. J Immunol 2006; 177:6263-6270.
85. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 2006; 203:1153-1159.
86. Marr N, Wang TI, Kam SH, et al. Attenuation of respiratory syncytial virusinduced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol 2014; 192:948-957.
87. Cormier SA, Shrestha B, Saravia J, et al. Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol 2014; 88:9350-9360.
88. Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014; 14:81-93.
89. Schneider C, Nobs SP, Heer AK, et al. Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. PLoS Pathog 2014; 10:e1004053.
90. Reed JL, Brewah YA, Delaney T, et al. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis 2008; 198:1783-1793.
91. Pribul PK, Harker J, Wang B, et al. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 2008; 82:4441-4448.
92. Kolli D, Gupta MR, Sbrana E, et al. Alveolar macrophages contribute to the pathogenesis of human metapneumovirus infection while protecting against respiratory syncytial virus infection. Am J Respir Cell Mol Biol 2014; 51:502-515.
93. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol 2013; 31:163-194.
94. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:1126-1136.
95. Li F, Zhu H, Sun R, et al. Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol 2012; 86:2251-2258.
96. Hussell T, Openshaw PJ. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8\+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 1998; 79 (Pt 11):2593-2601.
97. Kaiko GE, Phipps S, Angkasekwinai P, et al. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol 2010; 185:4681-4690.
98. Lee YC, Lin SJ. Neonatal natural killer cell function: relevance to antiviral immune defense. Clin Dev Immunol 2013; 2013:427696.
99. Merad M, Sathe P, Helft J, et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604.
100. de Graaff PM, de Jong EC, van Capel TM, et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. J Immunol 2005; 175:5904-5911.
101. Le Nouen C, Hillyer P, Winter CC, et al. Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus. PLoS Pathog 2011; 7:e1002105.
102. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31:705-742.
103. Chu HY, Englund JA. Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 2013; 372:235-258.
104. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708-715.
105. Ogilvie MM, Vathenen AS, Radford M, et al. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981; 7:263-271.
106. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009; 123:398-403.
107. Ochola R, Sande C, Fegan G, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One 2009; 4:e8088.
108. Brandenburg AH, Groen J, van Steensel-Moll HA, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52:97-104.
109. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189:233-238.
110. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006; 78:1493-1497.
111. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998; 177:463-466.
112. Luchsinger V, Piedra PA, Ruiz M, et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 2012; 54:905-912.
113. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980; 96:179-186.
114. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986; 315:77-81.
115. Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988; 168:1163-1168.
116. Graham BS, Bunton LA, Wright PF, et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991; 88:1026-1033.
117. Heidema J, Lukens MV, van Maren WW, et al. CD8\+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol 2007; 179:8410-8417.
118. Lukens MV, van de Pol AC, Coenjaerts FE, et al. A systemic neutrophil response precedes robust CD8(\+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 2010; 84:2374-2383.
119. Rossey I, Sedeyn K, De Baets S, et al. CD(8) T cell immunity against human respiratory syncytial virus. Vaccine 2014; 32:6130-6137.
120. Varga SM, Braciale TJ. The adaptive immune response to respiratory syncytial virus. Curr Top Microbiol Immunol 2013; 372:155-171.
121. Piedimonte G. Respiratory syncytial virus and asthma: speed-dating or longterm relationship? Curr Opin Pediatr 2013; 25:344-349.
122. Connors M, Giese NA, Kulkarni AB, et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalininactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994; 68:5321-5325.
123. Legg JP, Hussain IR, Warner JA, et al. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003; 168:633-639.
124. Semple MG, Dankert HM, Ebrahimi B, et al. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. PLoS One 2007; 2:e1038.
125. Kristjansson S, Bjarnarson SP, Wennergren G, et al. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J Allergy Clin Immunol 2005; 116:805-811.
126. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008; 82:2040-2055.
127. Moreno-Solis G, Torres-Borrego J, de la Torre-Aguilar MJ, et al. Analysis of the local and systemic inflammatory response in hospitalized infants with respiratory syncitial virus bronchiolitis. Allergol Immunopathol (Madr) 2014; S0301-S0546.
128. Christiaansen AF, Knudson CJ, Weiss KA, et al. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 2014; 59:109-117.
129. Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14:585-600.
130. Larranaga CL, Ampuero SL, Luchsinger VF, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J 2009; 28:867-873.
131. Faber TE, Groen H, Welfing M, et al. Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis. J Med Virol 2012; 84:1084-1088.
132. Stoppelenburg AJ, de Roock S, Hennus MP, et al. Elevated Th17 response in infants undergoing respiratory viral infection. Am J Pathol 2014; 184:1274-1279.
133. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011; 179:248-258.
134. Stoppelenburg AJ, Salimi V, Hennus M, et al. Local IL-17A potentiates early neutrophil recruitment to the respiratory tract during severe RSV infection. PLoS One 2013; 8:e78461.
135. de Almeida Nagata DE, Demoor T, Ptaschinski C, et al. IL-27R-mediated regulation of IL-17 controls the development of respiratory syncytial virusassociated pathogenesis. Am J Pathol 2014; 184:1807-1818.
136. Bystrom J, Al-Adhoubi N, Al-Bogami M, et al. Th17 lymphocytes in respiratory syncytial virus infection. Viruses 2013; 5:777-791.
137. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7:875-888.
138. Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. Nat Rev Immunol 2014; 14:343-349.
139. Lee DC, Harker JA, Tregoning JS, et al. CD25\+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010; 84:8790-8798.
140. Loebbermann J, Thornton H, Durant L, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol 2012; 5:161-172.
141. Krishnamoorthy N, Khare A, Oriss TB, et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med 2012; 18:1525-1530.
142. Raiden S, Pandolfi J, Payaslian F, et al. Depletion of circulating regulatory T cells during severe respiratory syncytial virus infection in young children. Am J Respir Crit Care Med 2014; 189:865-868.
143. Lühn K, Simmons CP, Moran E, et al. Increased frequencies of CD4\+ CD25(high) regulatory T cells in acute dengue infection. J Exp Med 2007; 204:979-985.
144. Giamarellos-Bourboulis EJ, Raftogiannis M, Antonopoulou A, et al. Effect of the novel influenza A (H1N1) virus in the human immune system. PLoS One 2009; 4:e8393.
145. Sakaguchi S, Vignali DA, Rudensky AY, et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013; 13:461-467.